AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00198029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc (hylan G-F20)
Description: 32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
Study NCT00521456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac eye drops
Description: 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo
Study NCT00521456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ketorolac eye drops
Description: 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo
Study NCT01143025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 50 mg
Description: Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
Study NCT01143025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 100 mg
Description: Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
Study NCT01143025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg
Description: Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
Study NCT04559607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab: 200mg, iv, Q3W
Study NCT04559607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE if necessary
Study NCT04559607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE if necessary
Study NCT04559607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 250m, po, QD
Study NCT02483637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RejuvenAir
Description: Device: RejuvenAir
Study NCT04414956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AFP-L3
Description: AFP-L3 will be tested using serum sample every 6 months.
Study NCT04414956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AFP
Description: AFP will be tested using serum sample every 6 months.
Study NCT04414956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PIVKA-II
Description: PIVKA-II will be tested using serum sample every 6 months.
Study NCT04414956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sonography
Description: Sonography will be tested by experts every 6 months.
Study NCT04414956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT
Description: Contrast-enhanced CT will be tested annually.
Study NCT02651636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: myo-inositol,alpha-lipoic acid and folic acid
Study NCT00646945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
Description: gas flow between 4 to 15 L/min
Study NCT00646945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50% Oxygen/50% Nitrogen premix
Description: gas flow between 4 to 15 L/min
Study NCT04337996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 diagnostic test
Description: COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
Study NCT01924390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mineralized freeze-dried bone allograft alone
Study NCT01924390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of Mineralized and demineralized freeze-dried bone allograft alone
Study NCT02710084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT03450577 — intervention group
Intervention type: PROCEDURE
Intervention: PCI of bifurcation lesions
Description: Different approaches for treatment of bifurcation coronary artery disease.
Study NCT03905304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medytoxin
Description: Intramuscular injection up to 300U.
Study NCT03905304 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Intramuscular injection up to 300U.
Study NCT01575548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01575548 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT01575548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01575548 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01575548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01575548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT04079686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephazolin
Description: Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
Study NCT04079686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
Study NCT01575548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01575548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03972930 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
Study NCT03684980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: (Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
Study NCT03684980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will be treated with rituximab 500 mg/m\^2.
Study NCT03684980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
Study NCT03684980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase 2000 units. Arm E 1000 units.
Study NCT01635374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-Oral Endoscopic Esophagomyotomy
Description: In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
Study NCT00921583 — intervention group
Intervention type: DEVICE
Intervention: Long-term examination
Description: Follow-up dental implants 20 year in function
Study NCT00472745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
Study NCT00472745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Diet for weight maintenance for 6 months
Study NCT02637687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
Study NCT04878939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power chain used for anterior segment retraction
Description: Elastomeric chain rendering 160 g/side extending between mini-screw implant and a hook crimped on 0.017- by 0.025-inch stainless steel wire distal to the lateral incisor.
Study NCT04878939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-loop fabricated to perform anterior segment retraction
Description: In the frictionless group, anterior segment retraction was done using closing T-loops fabricated from 0.017- by 0.025-inch titanium molybdenum alloy (TMA) wire rendering comparable retraction force.
Study NCT02590991 — intervention group
Intervention type: OTHER
Intervention: Prebiotics
Description: To study the long term effect of supplementation in early life
Study NCT03385473 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic index
Description: All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.
Study NCT03385473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic drug monitoring
Description: The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
Study NCT03562806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR image acquisition
Description: Acquisition of PET and MR sequences on SIGNA PET/MR device.
Study NCT04117607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
Study NCT03898960 — intervention group
Intervention type: DEVICE
Intervention: NIMBUS Device
Description: NIMBUS Geometric Clot Extractor
Study NCT02590991 — intervention group
Intervention type: OTHER
Intervention: Prebiotics & Probiotics
Description: To study the long term effect of supplementation in early life
Study NCT01630018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: 1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
Study NCT01630018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belotecan
Description: 0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
Study NCT00223665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
Study NCT00223665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
Study NCT01488552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Study NCT01488552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Study NCT01488552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Study NCT00600496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: twice daily oral dose
Study NCT00600496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: intravenous infusion
Study NCT00600496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: daily oral dose
Study NCT00600496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study NCT00600496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: intravenous infusion
Study NCT01488552 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) Analysis
Description: Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
Study NCT01488552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
Study NCT01488552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI
Description: 5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
Study NCT04408651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIIT.CI ACT
Description: 4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
Study NCT04408651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIIT.CI CFT
Description: 4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
Study NCT00624000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tpa (Alteplase) vs IA tpa (Alteplase)
Description: Alteplase was administered Either IA or IV x 1
Study NCT04117607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin
Description: Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Study NCT04117607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin
Description: Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
Study NCT00624000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV tpa (Alteplase) vs IA tpa (Alteplase)
Description: Alteplase was administered Either IA or IV x 1
Study NCT03295240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-I (bendamustine, rituximab, ibrutinib)
Description: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
Study NCT03295240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN (Venetoclax)
Description: The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
Study NCT02654158 — intervention group
Intervention type: DRUG
Intervention: Low-dose of Fuganlin Oral Liquid
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day
Study NCT02654158 — intervention group
Intervention type: DRUG
Intervention: High-dose of Fuganlin Oral Liquid
Description: less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day
Study NCT04387461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CG0070
Description: Engineered Oncolytic Adenovirus
Study NCT04387461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Immune checkpoint inhibitor, Monoclonal antibody
Study NCT04387461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: n-dodecyl-B-D-maltoside
Description: Transduction-enhancing agent.
Study NCT00701792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liver transplantation
Description: liver transplantation
Study NCT00701792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care for liver disease
Description: standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy.
Study NCT00971490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acu-TENS (Transcutaneous electrical nerve stimulation)
Description: Transcutaneous electrical nerve stimulation applied onto acupuncture point
Study NCT00971490 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acu-TENS (Transcutaneous electrical nerve stimulation)
Description: Similar to Group 1 but without electrical stimulation
Study NCT00971490 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acu-TENS (Transcutaneous electrical nerve stimulation)
Description: Similar to Group 1 but applied onto non acupuncture point
Study NCT03461458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
Study NCT03153527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
Study NCT03153527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
Study NCT00972478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00972478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00972478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00972478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV
Study NCT00972478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV